Home MarketDr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. Stock Info: As on 2017-11-24 15:59:42

Nse

889.90

0.20(0.02%)
Change%
52 Week Range
723.05
24.00
1,215.00
24.00
Open890.00
Day's Range711.76 - 1,067.64
Value Traded (in ₹ Cr.) 9.65

Bse

888.45

-0.40(-0.05%)
Change %
52 Week Range
717.65
24.00
1,220.00
24.00
Open890.00
Day's Range711.08 - 1,066.62
Value Traded (in ₹ Cr.) 0.36

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 48,265,226.00 57.92%
Mutual Funds/UTI 8,361,586.00 10.03%
FII 8,954,308.00 10.75%
Employee 0.00 0.00%
Public 3,985,832.00 4.78%
Government 0.00 0.00%
Others 11,288,273.00 13.55%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 9.95
Basic EPS (Rs.) 15.31
Cash EPS 19.08
BVPerShare Excl 57.88
Operating Revenue 92.58
PBDITPerShare 27.12
Dividend 2.45
NPPerShare 15.21
Current Ratio 4.68
Quick Ratio 4.52
PriceToBV 15.92
Earnings 0.01
PBDIT Margin 29.29
PBT Margin 25.05
NP Margin 16.42
Return On Assets 21.25
Retention Ratios 83.87
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 785.81
Total Expenses 594.05
EBITDA 224.25
PBT 191.75
PAT 125.75
Net Income 125.75
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 384.69
Total Expenses 268.78
EBITDA 99.39
PBT 132.23
PAT 92.43
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 82.68
Net worth 478.51
Investments 74.18
Total Liability 591.72
Total debt 0.00
Net block 133.88
Total Assets 591.72
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 81.26
Net worth 319.24
Investments 49.36
Total Liability 449.18
Total debt 0.00
Net block 119.97
Total Assets 449.18
Company Curr Price Prev. Close Change% W's Low/High

Apollo Hospitals Enterprise Ltd.

1145.2 1139.55 0.5
1023.81157

Fortis Healthcare Ltd.

138.75 132 5.11
123.4133.7

Healthcare Global Enterprises Ltd.

296.5 298.4 -0.64
281303

Indraprastha Medical Corporation Ltd.

50.75 51.1 -0.68
50.2551.5

Kovai Medical Center and Hospital Ltd.

641.65 624.85 2.68
629.9649.9

Lotus Eye Hospital and Institute Ltd.

33.2 34 -2.35
31.435.95

Marico Kaya Enterprises Ltd.

1547.05 1582.55 -2.24
1535.051589
Company Curr Price Prev. Close Change% W's Low/High

ADS Diagnostic Ltd.

11.34 10.8 0
11.3411.34

Apollo Hospitals Enterprise Ltd.

1141.5 1135.15 0.56
1023.91152.45

Birla Pacific Medspa Ltd.

0.28 0.27 0
0.270.28

CDR Health Care Ltd.

7.58 2.6 0
7.227.58

Chennai Meenakshi Multispeciality Hospital Ltd.

12.1 12.7 -4.72
12.112.1

Dhanvantri Jeevan Rekha Ltd.

34 35.05 -3
31.3536.2

Dolphin Medical Services Ltd.

1.03 1.03 0
0.921.05
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 142.25
Cash from investing activities -148.14
Cash from financing activities 0.99
Net change in cash -4.89

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Franklin India Prima Plus 1.31%
SBI Magnum Balanced Fund 0.74%
Franklin India Smaller Companies Fund 0.93%
SBI Magnum Midcap Fund 1.54%
SBI Magnum Global Fund 1.64%
Franklin India Prima Fund 0.81%

Excel Industries Q2 net profit jumps 60.26% at Rs 11.01 cr

The company reported standalone net profit of Rs 11.01 crore for the quarter ended September 30, 2017 as compared to Rs 6.87 crore in the same period last year, registering a year-on-year growth of 60.26 per cent. Net revenue of the company rose moderately by 6.02 per cent at Rs 130.02 crore in July-September quarter of this fiscal as against Rs 122.64 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 0.72 per cent to Rs 108.27 crore from Rs 109.05 crore in year ago period. Other Income dipped by 71.76 per cent at Rs 0.24 crore versus (Sep'16 Rs 0.85 crore). Operating Profit surged by 45.68 per cent to Rs 21.75 crore as against Rs 14.93 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 37.36 per cent in September quarter. Interest declined by 47.90 per cent y-o-y to Rs 1.61 crore, while Taxation increased by 156.31 per cent at Rs 5.69 crore (Sep'16 Rs 2.22 crore).

24-11-2017 16:50

Skyline Millars posts Q2 net loss of Rs 0.16 cr

The company reported standalone net loss during the quarter stood at Rs 0.16 crore compared to net profit of Rs 0.53 crore in the previous year quarter. Net revenue of the company rose two fold by 245.45 per cent at Rs 1.14 crore in July-September quarter of this fiscal as against Rs 0.33 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 7.37 per cent to Rs 1.02 crore from Rs 0.95 crore in year ago period. Other Income dipped by 99.43 per cent at Rs 0.01 crore versus (Sep'16 Rs 1.74 crore). Operating Profit surged by 119.35 per cent to Rs 0.12 crore as against Rs -0.62 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 105.56 per cent in September quarter.

24-11-2017 16:40

Kingfa Science & Technology Q2 net profit up 21.77%

The company reported standalone net profit of Rs 5.09 crore for the quarter ended September 30, 2017 as compared to Rs 4.18 crore in the same period last year, registering a year-on-year growth of 21.77 per cent. Net revenue of the company rose substantially by 24.78 per cent at Rs 139.87 crore in July-September quarter of this fiscal as against Rs 112.09 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 23.44 per cent to Rs 130.01 crore from Rs 105.32 crore in year ago period. Other Income grew by 1058.33 per cent at Rs 1.15 crore versus (Sep'16 Rs -0.12 crore). Operating Profit surged by 45.86 per cent to Rs 9.86 crore as against Rs 6.76 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 16.92 per cent in September quarter. Interest grew by 257.75 per cent y-o-y to Rs 1.12 crore, while Taxation increased by 68.61 per cent at Rs 3.76 crore (Sep'16 Rs 2.23 crore).

24-11-2017 16:30

Valiant wins orders worth Rs 5 cr for metro projects

Valiant Communications on Friday said it has received the product approvals and letter of intents for supply of its communication solutions for Kolkata Metro Rail Corporation and Dedicated Freight Corridor projects for western Region. “The gross value of the projects exceeds Rs 5 crore,” Valiant Communications said in a filing to the Bombay Stock Exchange. Commenting on the development, Inder Mohan Sood, Managing Director said: “These are significant developments, as it also opens up the railway sector for the company to participate in the upgradation of Indian Railways.” Meanwhile, shares of company closed trade at Rs 84.00 apiece, up 6.94 per cent, on the BSE today.

24-11-2017 16:16

Alexander Stamps Q2 net profit up 6.25% at Rs 0.17 cr

The company reported standalone net profit of Rs 0.17 crore for the quarter ended September 30, 2017 as compared to Rs 0.16 crore in the same period last year, registering a year-on-year growth of 6.25 per cent. Net revenue of the company declined substantially by 57.74 per cent at Rs 1.31 crore in July-September quarter of this fiscal as against Rs 3.10 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 62.76 per cent to Rs 1.08 crore from Rs 2.90 crore in year ago period. Operating Profit surged by 15.00 per cent to Rs 0.23 crore as against Rs 0.20 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 169.71 per cent in September quarter. Taxation increased by 40.00 per cent at Rs 0.07 crore (Sep'16 Rs 0.05 crore).

24-11-2017 15:10

Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

24-Nov-2017 04:50 PM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings are as per attachment

24-Nov-2017 04:50 PM

Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

16-Nov-2017 06:09 PM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings as per attachment

16-Nov-2017 06:09 PM

Dr. Lal Pathlabs Ltd - Investor Presentation

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Investor Presentation

10-Nov-2017 05:23 PM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings are as per attachment

24-Nov-2017 04:50 PM

Dr. Lal Pathlabs Ltd - Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of proposed schedule of Analyst/Institutional Investor meetings as per attachment

16-Nov-2017 06:09 PM

Dr. Lal Pathlabs Ltd - Investor Presentation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), please find attached herewith Corporate Presentation of the Company, which the Company proposes to share with analysts/investors.

10-Nov-2017 05:16 PM

Corporate Details

About Management

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company.

Registered Office

12th Floor, Tower B, SAS Tower, Sector 38, Medicity,

0124-3016500,,,      0124-4234468,

cs@lalpathlabs.com

https://www.lalpathlabs.com

Registrar Details

Link Intime India Pvt. Ltd.